Dr. Carrizosa on the Efficacy Findings of the CRESTONE Trial in NRG1 Fusion–Positive Solid Tumors

In Partnership With:

Partner | Cancer Centers | <b>Atrium Health Levine Cancer Institute</b>

Daniel Carrizosa, MD, MS, discusses the efficacy findings of the phase 2 CRESTONE trial in patients with NRG1 fusion–positive, advanced solid tumors.

Daniel Carrizosa, MD, MS, oncologist, Head and Neck Cancer Lung Cancer, Hematology and Medical Oncology (Cancer), Atrium Health Levine Cancer Institute (Thoracic-Pulmonary), discusses the efficacy findings of the phase 2 CRESTONE trial (NCT04383210) in patients with NRG1 fusion–positive, advanced solid tumors.

The phase 2, open-label, international trial evaluated seribantumab in patients with recurrent, locally advanced and/or metastatic solid tumors that harbor NRG1fusions.

Data presented at the 2022 Annual ASCO Meeting showed seribantumab displayed both good efficacy and safety, Carrizosa says. As of April 2022, the investigator-assessed overall response rate (ORR) was 33% with a disease control rate of 92% among 12 evaluable patients, Carrizosa explains. Notably, most patients enrolled with NRG1 fusion–positive non–small cell lung cancer, and this subgroup achieved an ORR of 36%, Carrizosa adds.

Among all patients, there were 2 partial responses and 2 complete responses, leading to promise that seribantumab produced antitumor activity in patients with NRG1 fusions, Carrizosa concludes.